Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

FSS Puts a Break on Hyundai Motor Securities Rights Offering

CHA Biotech Announces A Capital Raise of 41% of Outstanding Shares

Hyundai Motor Securities: FSS Approves A 200 Billion Won Capital Raise + Rising Real Estate PF Risk

Hyundai Motor Securities Announces a Rights Offering Involving a 49% Shares Dilution

Korea Zinc - Rights Offering of 2.5 Trillion Won Is a Display Of "Korea Discount" At Its Worst

Korea Zinc: Increased Volatility in Share Price Post Korea Zinc's Tender Offer Results

Douglas Research Advisory

Equity Capital Markets

<ul>
<li>In this insight, we review the major rights offerings/capital raises that were announced in Korea in 2024.</li>
<li>In general, the major rights offerings/capital raises tend to result in lower share prices one month, three months, and over a longer time frame. </li>
<li>There are some exceptions. Peptron and ABL Bio experienced higher share prices even after their capital raise announcements, especially after a longer time frame (3 months or more).</li>
</ul>


In this insight, we review the major rights offerings/capital raises that were announced in Korea in 2024.
In general, the major rights offerings/capital raises tend to result in lower share prices one month, three months, and over a longer time frame. 
There are some exceptions. Peptron and ABL Bio experienced higher share prices even after their capital raise announcements, especially after a longer time frame (3 months or more).


A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024